Here are the DEF 14A proxy statements from Silence Therapeutics Plc (SLN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLN filings page.
Silence Therapeutics plc has released proxy materials for its 2026 Annual General Meeting, a hybrid meeting on June 16, 2026 in Hoboken, NJ and online. Shareholders will vote on nine ordinary resolutions, including re-appointing directors Rhonda Hellums and James Ede-Golightly, an advisory say-on-pay, and multiple auditor items involving PricewaterhouseCoopers LLP.
Other proposals cover receiving and adopting the 2025 U.K. Annual Report, approving the U.K. statutory directors’ annual report on remuneration, and continuing takeover protections in Article 159 of the articles of association. Ordinary resolutions pass with a simple majority of votes cast. There were 141,703,839 ordinary shares issued and outstanding as of April 24, 2026.